This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Alamar Biosciences Launches...
Tech product launch

Alamar Biosciences Launches NULISAseq Neuro 220 Panel

Analysis based on 7 articles · First reported Mar 17, 2026 · Last updated Mar 17, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The launch of the NULISAseq Neuro 220 Panel by Alamar Biosciences is expected to positively impact the biotechnology and healthcare sectors by advancing neurodegenerative disease research and diagnostics. This innovation could lead to earlier disease detection and more effective therapies, benefiting patients and potentially creating new market opportunities.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Alamar Biosciences launched its NULISAseq Neuro 220 Panel, a new product designed for multiplexed measurement of 220 biomarkers from a single sample with ultra-high sensitivity and specificity. This panel expands on their existing CNS Disease Panel 120 and includes 15 new biomarkers developed with support from The The Michael J. Fox Foundation, as well as 12 assays specific to brain and peripheral Tau isoforms. The NULISAseq Neuro 220 Panel is applicable to a wide range of neurological disorders, including Alzheimer's disease and Parkinson's disease, and supports pre-symptomatic detection. Data on the panel's utility will be presented at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026) in Copenhagen, Denmark, by Dr. Henrik Zetterberg.

Key Actions
100 Alamar Biosciences launched NULISAseq Neuro 220 Panel
70 The Michael J. Fox Foundation supported biomarker development Alamar Biosciences
Entities Involved
priv
Alamar Biosciences
Alamar Biosciences launched its NULISAseq Neuro 220 Panel, expanding its offerings for neurodegenerative disease research. This product launch is expected to enhance Alamar Biosciences' position in precision proteomics and contribute to its growth.
Importance 100 Sentiment 70
ngo
The Michael J. Fox Foundation
The The Michael J. Fox Foundation supported the development of new biomarkers included in the NULISAseq Neuro 220 Panel. This collaboration helps advance Parkinson's disease research and diagnostic tools.
Importance 70 Sentiment 50
per
Yuling Luo
Yuling Luo, founder, chairman, and CEO of Alamar Biosciences, highlighted the company's continued innovation in precision proteomics with the launch of the NULISAseq Neuro 220 Panel.
Importance 60 Sentiment 50
per
Nicole Polinski
Nicole Polinski, Director of Research Programs at The The Michael J. Fox Foundation, expressed pride in supporting Alamar Biosciences' development of sensitive assays for Parkinson's disease research.
Importance 40 Sentiment 50
per
Henrik Zetterberg
Henrik Zetterberg, Professor of Neurochemistry at the University of Gothenburg, will present data on the NULISAseq Neuro 220 Panel at AD/PD 2026, emphasizing its significance for translational and clinical research.
Importance 40 Sentiment 50
Relationships
Alamar Biosciences related ↔ The Michael J. Fox Foundation
Yuling Luo related ↔ Alamar Biosciences
Nicole Polinski related ↔ The Michael J. Fox Foundation
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.